Novel strategies for managing dyslipidemia: Treatment beyond statins

Postgraduate Medicine

Volumn 124, Issue 6, 2012, Pages 43-54

  Ling, Hua ^a   Burns, Tammy L ^a   Hilleman, Daniel E ^b  

^a CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

Author keywords

Atherosclerosis; Dyslipidemia; Hyperlipidemia; Lipid lowering drugs

Indexed keywords

ALIROCUMAB; AMG 145; ANACETRAPIB; ANTILIPEMIC AGENT; APOLIPOPROTEIN B INHIBITOR; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EPROTIROME; EVACETRAPIB; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PLACEBO; PRAVASTATIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; ROSUVASTATIN; SIMVASTATIN; THYROMIMETIC AGENT; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; APOLIPOPROTEIN B; CARRIER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PCSK9 PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SERINE PROTEINASE;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; DIABETES MELLITUS; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; LEUKOCYTOCLASTIC VASCULITIS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); SIDE EFFECT; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG POTENTIATION; REVIEW; RISK FACTOR;

APOLIPOPROTEINS B; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROPROTEIN CONVERTASES; RISK FACTORS; SERINE ENDOPEPTIDASES;

MLCS; MLOWN;

EID: 84875792307     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.11.2612     Document Type: Article

References (80)

1. Omran AR. The epidemiologic transition. A theory of the epidemiology of population change. Milbank Mem Fund Q. 1971;49(4):509-538.
2. Mackenbach JP. The epidemiologic transition theory. J Epidemiol Comm Health. 1994;48(4):329-311.
3. Moriyama IM. The change in mortality trend in the United States. Vital Health Stat 1. 1964;127:1-43.
4. Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham study. Am J Public Health Nations Health. 1957;47(4 pt 2):4-24.
5. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41(3):279-281.
6. Dawber TR, Kannel WB, Revotskie N, Stokes J 3rd, Kagan A, Gordon T. Some factors associated with the development of coronary heart disease: six years' follow-up experience in the Framingham study. Am J Public Health Nations Health. 1959;49:1349-1356.
7. Dawber TR, Kannel WB. Susceptibility to coronary heart disease. Mod Concepts Cardiovasc Dis. 1961;30:671-675.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
9. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J. 1978;40(10):1069-1118.
10. Clofibrate and niacin in coaronary heart disease. JAMA. 1975; 231(4):360-381.
11. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245-1255.
12. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351-364.
13. Frick M, Elo O, Haapa K, et al. Helsinki Heart Study: primary- prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. JAMA. 1987;317(20):1237-1245.
14. The treatment of cerebrovascular disease with clofibrate. Final report of the Venterans Administration Cooperative Study of Atherosclerosis, Neurology Section. Stroke. 1973;4(4):684-693.
15. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102(1):21-27.
16. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002;325(7373):1139.
17. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in me with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410-418.
18. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
19. Baigent C, Blackwell L, Emberson J, et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753): 1670-1681.
20. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-2016.
21. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
22. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvas-tatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-1504.
23. de Lemos JA, Blazing MA, Wiviott SD, et al; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292(11):1307-1316.
24. Pedersen TR, Faergeman O, Kastelein JJ, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437-2445.
25. Kjekshus J, Apetrei E, Barrios V, et al; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-2261.
26. Tavazzi L, Maggioni AP, Marchioli R, et al; GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, palcebo-controlled trial. Lancet. 2008;372(9645):1231-1239.
27. Wanner C, Krane V, März W, et al; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-248.
28. Fellström BC, Jardine AG, Schnieder RE, et al; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-1407.
29. Holdaas H, Fellström B, Jardine AG, et al; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024-2031.
30. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785-794.
31. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10(18):2973-2985.
32. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.
33. Barter P, Gotto AM, LaRosa JC, et al; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301-1310.
34. Miller M, Cannon CS, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7): 724-730.
35. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172(2):144-152.
36. www.FDA.gov. US Food and Drug Administration website. FDA expands advice on statin risks. http://www.fda.gov/ForConsumers/Con-sumerUpdates/ucm293330.htm#2. Updated August 9, 2012. Accessed May 25, 2012.
37. Rossebø AB, Pedersen TR, Boman K, et al; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343-1356.
38. Ginsberg HN, Elam MB, Lovato LC, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.
39. Boden WE, Probstfield JL, Anderson T, et al; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267.
40. Tall AR. Plalsma cholesteryl ester transfer protein. J Lipid Res. 1993;34(8):1255-1274.
41. Gurfinkel R, Joy TR. Anacetrapib: hope for CETP inhibitors? Cardiovasc Ther. 2011;29(5):327-339.
42. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-2122.
43. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood presure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154(7):1465-1473.
44. Fayad ZA, Mani V, Woodward M, et al; dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378(9802):1547-1559.
45. Lüscher TF, Taddei S, Kaski JC, et al; dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33(7):857-865.
46. Schwartz GG, Olsson AG, Ballantyne CM, et al; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158(6): 896-901.
47. Roche provides update on phase III study of dalcetrapib [media release]. Basel, Switzerland: Roche; May 7, 2012. http://www.roche.com/media/media_releases/med-cor-2012-05-07.htm. Accessed May 25, 2012.
48. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306(19):2099-2109.
49. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157(2):352-360.
50. Cannon CP, Shah S, Dansky HM, et al; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25): 2406-2415.
51. www.ClinicalTrials.gov. REVEAL: Randomized Evaluation of the Effects of Anacetrapib Through Lipid-Modification. NCT01252953. http://clinicaltrials.gov/ct2/show/NCT01252953?term=NCT0125295 3&rank=1. Accessed May 25, 2012.
52. Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis. 2009;203(1):1-7.
53. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade [published online ahead of print July 17, 2012]. J Lipid Res.
54. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272.
55. Awan Z, Seidah NG, MacFadyen JG, et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem. 2012;58(1):183-189.
56. Abifadel M, Pakradouni J, Collin M, et al. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin Ther Pat. 2010;20(11):1547-1571.
57. Dias C, Shaywitz A, Cooke B, et al. Effects of AMG 145, a fully human monoclonal antibody against pcsk9, on low-density lipoprotein cholesterol in subjects taking statins: a phase 1, randomized, double-blind, placebo-controlled, ascending multiple-dose study. J Am Coll Cardiol. 2012;59(13 s1):E1379-E1379.
58. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344-2353.
59. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolae-mia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29-36.
60. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A. 1999;96(22):12766-12771.
61. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res. 2007;56(2):91-98.
62. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/ gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374(9684):126-135.
63. www.ClinicalTrials.gov. A Study with Aleglitazar in Patients with a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus. NCT01042769. http://clinicaltrials.gov/ct2/show/NCT01042769. Accessed May 25, 2012.
64. Ito MK. ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense? Ann Pharmacother. 2007;41(10):1669-1678.
65. Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J. 2012;33(12):1451-1458.
66. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356(2):148-156.
67. KYNAMRO (mipomersen sodium). Isis Pharmaceuticals, Inc. website. http://www.isip.com/Pipeline/Therapeutic-Areas/Cardiovascularhtm#Mipomersen. Accessed May 25, 2012.
68. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998-1006.
69. US Food and Drug Administration; US Department of Health and Human Services. Briefing information for the October 18, 2012 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/drugs/ endocrinologicandmetabolicdrugsadvisorycommittee/ucm323925.htm. Accessed December 6, 2012.
70. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res. 2003;44(1):22-32.
71. Zamel R Khan R, Pollex RL, Hegele RA. Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis. 2008;3:19.
72. FDA grants orphan drug designation to aegerion pharmaceuticals' drug candidate, lomitapide, for treatment of familial chylomicronemia [press release]. Aegerion Pharmaceuticals, Inc.; March 15, 2011. http://ir.aegerion.com/releasedetail.cfm?releaseid=557106. Accessed May 25, 2012.
73. Aegerion pharmaceuticals announces lomitapide 78-week phase III clinical data consistent with earlier results [press release]. Aegerion Pharmaceuticals, Inc.; January 6, 2012. http://ir.aegerion.com/releasedetail. cfm?ReleaseID=637610. Accessed May 25, 2012.
74. Cuchel M, Meagher EA, Marais AD, et al. L5 phase 3 study of microsomal triglyceride transfer protein inhibitor (MTP-i) lomitapide in subjects with homozygous familial hypercholesterolemia (HOFH): 56-week results. Atherosclerosis Supplements. 2010;11(2):14.
75. US Food and Drug Administration; US Department of Health and Human Services. Briefing information for the October 17, 2012 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/drugs/ endocrinologicandmetabolicdrugsadvisorycommittee/ucm323840.htm. Accessed December 6, 2012.
76. Shin JJ, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2). J Biol Chem. 2003;278(36):34114-34118.
77. Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov. 2009;8(4):308-320.
78. Grover GJ, Mellström K, Ye L, et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A. 2003;100(17):10067-10072.
79. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010;362(10):906-916.
80. Karo Bio terminates the eprotirome program [press release]. Stockholm, Sweden: Karo Bio AB; February 14, 2012. http://www.karobio.com/inves-tormedia/pressreleaser/pressrelease?pid=639535. Accessed May 25, 2012.